FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/New Phase III Study Aims to Assess Tirzepatide’s Impact on Adolescent Obesity
返回研究图书馆

New Phase III Study Aims to Assess Tirzepatide’s Impact on Adolescent Obesity

May 25, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

New Phase III Study Aims to Assess Tirzepatide’s Impact on Adolescent Obesity

A new clinical trial has begun evaluating the effectiveness of tirzepatide, a promising peptide-based treatment, in managing obesity and related health issues among adolescents. The study, titled "SURMOUNT-ADOLESCENTS-2" (NCT06439277) and sponsored by Eli Lilly and Company, is currently recruiting participants for its Phase III stage.

Background

Adolescent obesity has become a significant public health concern worldwide, often leading to severe comorbidities such as cardiovascular diseases, type 2 diabetes, and mental health issues. Traditional weight management approaches like diet and exercise can be challenging for adolescents, who face unique physiological and environmental factors. The development of new therapeutic options like tirzepatide, a dual glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, offers hope for more effective intervention strategies.

Tirzepatide has already shown promise in adult populations, with previous studies demonstrating significant reductions in body weight and improvements in cardiometabolic risk factors. However, its efficacy and safety in younger patients remain unexplored on a large scale until now. This new study aims to bridge this gap by assessing how tirzepatide interacts with lifestyle modifications like diet and exercise to combat obesity and associated conditions in adolescents.

Key Details

The "SURMOUNT-ADOLESCENTS-2" trial is set to enroll approximately 300 participants aged between 12 and 18 years who have been diagnosed with obesity and at least one weight-related comorbidity. The study will span around 76 weeks, during which participants will be randomly assigned either tirzepatide or a placebo while also receiving guidance on healthy nutrition and physical activity.

Researchers will closely monitor changes in bodyweight, cardiovascular risk factors (such as blood pressure, cholesterol levels), and other health indicators throughout the trial period. Additionally, safety assessments will include evaluating adverse events and conducting regular laboratory tests to ensure that tirzepatide remains safe for use in this younger demographic.

The primary objective is to determine whether adding tirzepatide to a regimen of healthy lifestyle habits can lead to clinically meaningful reductions in body weight and improvements in overall health outcomes compared to placebo. Secondary objectives include assessing long-term safety, adherence rates, and the impact on quality of life measures among participants.

Key Takeaways

  • Efficacy Evaluation: The study aims to determine if tirzepatide is effective in reducing obesity and improving cardiovascular risk factors when combined with lifestyle modifications.
  • Safety Monitoring: Comprehensive assessments will be conducted to ensure the safety profile of tirzepatide in adolescent populations over an extended period.
  • Comparative Analysis: Participants will receive either active treatment or placebo, allowing researchers to compare outcomes between groups accurately.
  • Comprehensive Follow-Up: Extensive monitoring throughout the study will provide valuable insights into long-term effects and patient experiences.

What This Means

For the peptide community, this trial represents a crucial step forward in understanding how advanced therapies like tirzepatide can be used effectively across different age groups. Given the growing prevalence of adolescent obesity and related health issues, such research is essential for developing targeted interventions that address these specific needs. If successful, the findings from "SURMOUNT-ADOLESCENTS-2" could pave the way for broader use of peptide-based treatments in pediatric settings, potentially transforming how we approach weight management and preventive care.

---

Source: ClinicalTrials.gov — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。